Valerie Harper's Resilience and What Lung Cancer Really Is

Ten years, two diagnoses

Valerie Harper played Rhoda Morgenstern on The Mary Tyler Moore Show and then on Rhoda. CURE reports that she was diagnosed with lung cancer in 2009.

In 2013 came a second diagnosis: leptomeningeal carcinomatosis, meaning cancer had reached the membranes around her brain. She talked about it publicly. In a 2015 interview she said, "I was supposed to be dead in three months, so you don't quiver when it's been two years and two months." She urged other patients to "stay fighting and continue on this amazing path of new ideas for treating and conquering cancer."

She died on August 30, 2019, at the age of 80.

Her case is often told as a story about beating the odds. The more useful reading is about what odds actually are, and that is where this page goes.

Why the second diagnosis was still lung cancer

The National Cancer Institute sets out the naming rule that confuses almost everyone: "Metastatic cancer has the same name as the primary cancer. For example, breast cancer that spreads to the lung is called metastatic breast cancer, not lung cancer."

Cancer that starts in the lung and reaches the brain lining is not brain cancer. It is lung cancer in a new place, and it is treated with lung cancer drugs chosen for that cancer's biology.

NCI divides lung cancer into two main groups, non-small cell and small cell. Non-small cell is the larger group. NCI's clinician guidance names its three main subtypes and gives each as a share of all lung cancers: adenocarcinoma at 40 percent, squamous cell carcinoma at 25 percent, and large cell carcinoma at 10 percent.

What leptomeningeal carcinomatosis actually is

The leptomeninges are the thin membranes wrapping the brain and spinal cord, with cerebrospinal fluid circulating between them. When cancer cells enter that fluid, they can seed anywhere the fluid travels, which is why the symptoms are scattered rather than localized.

StatPearls, a peer-reviewed clinical reference, reports that metastatic breast cancer is the most common cause, followed by lung cancer and melanoma. Symptoms in the brain include headache, confusion, cognitive impairment, psychiatric changes, and seizures. Symptoms in the spine include limb weakness, patchy sensory loss, radiating pain, and bladder or bowel dysfunction.

Diagnosis takes two tools. MRI with gadolinium contrast has a sensitivity of 70 percent and a specificity of 77 to 100 percent. The other is a lumbar puncture, a needle draw of spinal fluid, examined for cancer cells. StatPearls notes that this cytology test "can yield false negatives of up to 36%" when the sample is not handled well, which is why the tap is sometimes repeated.

Treatment usually combines radiation with intrathecal chemotherapy, meaning drugs delivered directly into the spinal fluid, alongside systemic treatment.

The number she was given, and what such numbers mean

StatPearls reports that with leptomeningeal carcinomatosis, "the time from diagnosis to death is about 4 to 6 weeks if left untreated," and that "with treatment, overall survival is approximately 2 to 4 months."

Those are medians. A median is the midpoint of a group, which means half of that group lived longer, some of them far longer. A median is not a countdown clock issued to an individual, and it cannot be, because it is calculated from people who were treated in past years with the tools available then.

Harper lived about six years past that second diagnosis. That does not make the statistic wrong, and it does not mean anyone else should expect the same. It means the statistic describes a distribution, and people live at every point along it.

When to get checked

Two symptom sets matter here. The first is lung.

• A cough that is new, or an old cough that has changed, lasting more than three weeks
• Coughing up blood, even a single streak
• Chest pain worse with a deep breath, new wheezing, or breathlessness doing what used to be easy
• Pneumonia twice in a year, unplanned weight loss, or hoarseness lasting weeks

The second set applies to anyone with a cancer history, and it should be reported the same week rather than at the next scheduled visit.

• A new headache pattern, especially one worst on waking
• Confusion, memory trouble, or a personality change that others notice
• Double vision, a first-ever seizure, or new hearing loss on one side
• Weakness or numbness in a limb, new trouble walking, or a change in bladder or bowel control

Screening, for the people it applies to

Screening finds cancer before symptoms appear. CDC states the U.S. Preventive Services Task Force recommendation: a yearly low dose CT scan for people aged 50 to 80 with a 20 pack year or greater smoking history who smoke now or quit within the past 15 years. A pack year is an average of one pack a day for one year.

NCI reports the benefit and the cost side by side. Yearly low dose CT for three years found more early lung cancer than chest x-rays and reduced lung cancer deaths in current and former heavy smokers. It also produced false alarms leading to unneeded procedures, some overdiagnosis, and repeated radiation exposure.

Screening criteria are built around smoking history. They do not cover people who never smoked, which is one reason symptoms in never-smokers get taken less seriously than they should be.

The testing that changed this disease

Modern lung cancer treatment starts with the tumor's genetics. NCI reports that EGFR variants "strongly predict the improved response rate and progression free survival of patients who take EGFR inhibitors." ALK gene fusions appear in 3 to 7 percent of cases and respond to ALK inhibitors. NCI lists further targets including BRAF, ROS1, RET, NTRK, MET, KRAS, and HER2. Immunotherapy, which NCI describes as treatment that "helps a person's immune system fight cancer," adds another route.

Note the exact wording on EGFR. It says response rate and progression-free survival, which measure whether and for how long a tumor is held in check. That is not the same claim as living longer overall, and the difference is worth holding onto when reading any drug headline.

What the population figures say

SEER, the federal cancer surveillance program, reports five-year relative survival for lung and bronchus cancer at 65.5 percent for localized disease, 38.2 percent when regional lymph nodes are involved, and 10.5 percent once it has spread to distant sites, drawn from cases diagnosed in 2016 through 2022. SEER records 51 percent of cases as already distant at diagnosis and 24 percent as localized. For 2026, American Cancer Society projections reprinted by SEER give 229,410 new cases and 124,990 deaths.

Every one of those figures is a group average. None of them was ever about one person.

Sources

• https://www.curetoday.com/view/remembering-the-life-and-legacy-of-valerie-harper
• https://www.cancer.gov/types/metastatic-cancer
• https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
• https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
• https://www.cancer.gov/types/lung/patient/lung-screening-pdq
• https://www.ncbi.nlm.nih.gov/books/NBK499862/
• https://seer.cancer.gov/statfacts/html/lungb.html
• https://www.cdc.gov/lung-cancer/screening/index.html